Patents by Inventor Christian Klein

Christian Klein has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AGAINST HUMAN ANGIOPOIETIN 2
    Publication number: 20230227543
    Abstract: The present invention relates to antibodies against human Angiopoietin 2 (anti-ANG-2 antibodies), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: March 31, 2023
    Publication date: July 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Ulrich Brinkmann, Remko Albert Griep, Klaus Kaluza, Anita Kavlie, Christian Klein, Joerg Thoms Regula, Werner Scheuer
  • COMBINATION THERAPY OF A TYPE II ANTI-CD20 ANTIBODY WITH A SELECTIVE BCL-2 INHIBITOR
    Publication number: 20230226045
    Abstract: The present invention is directed to a combination therapy involving a type II anti-CD20 antibody and a selective Bcl-2 inhibitor for the treatment of a patient suffering from cancer, particularly, a CD20-expressing cancer.
    Type: Application
    Filed: January 20, 2023
    Publication date: July 20, 2023
    Applicants: GENENTECH, INC., HOFFMANN-LA ROCHE INC., ABBVIE INC.
    Inventors: Deepak Sampath, Christian Klein, Wayne John Fairbrother, Sari L. Heitner Enschede, Rod A. Humerickhouse, Andrew W. Roberts, John F. Seymour
  • ANTIBODIES BINDING TO GPRC5D
    Publication number: 20230212308
    Abstract: The present invention generally relates to antibodies that bind to GPRC5D, including bispecific antigen binding molecules e.g. for activating T cells. In addition, the present invention relates to polynucleotides encoding such antibodies, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the antibodies, and to methods of using them in the treatment of disease.
    Type: Application
    Filed: September 23, 2022
    Publication date: July 6, 2023
    Inventors: Georg FERTIG, Christian Klein, Stefan Lorenz, Wei Xu, Marie-Luise Bernasconi, Alexander Bujotzek
  • TRISPECIFIC ANTIBODIES SPECIFIC FOR HER2 AND A BLOOD BRAIN BARRIER RECEPTOR AND METHODS OF USE
    Publication number: 20230212312
    Abstract: The present invention relates to trispecific antibodies binding to HER2 and a blood-brain barrier receptor (BBB-R), methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: June 10, 2022
    Publication date: July 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christian KLEIN, Julia KRUEGER, Ekkehard MOESSNER, Jens NIEWOEHNER
  • BISPECIFIC ANTI-VEGF/ANTI-ANG-2 ANTIBODIES AND THEIR USE IN THE TREATMENT OF OCULAR VASCULAR DISEASES
    Publication number: 20230212277
    Abstract: The present invention relates to bispecific antibody against human vascular endothelial growth factor (VEGF/VEGF-A) and against human angiopoietin-2 (ANG-2) of human IgG1 or IgG4 subclass with mutations I253A, H310A, and H435A, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Application
    Filed: December 23, 2022
    Publication date: July 6, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Harald Duerr, Frank Herting, Christian Klein, Joerg Thomas Regula, Matthias Rueth, Kay-Gunnar Stubenrauch
  • IMMUNOCONJUGATES
    Publication number: 20230192795
    Abstract: The present invention generally relates to mutant interleukin-7 polypeptides, immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-7 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the mutant interleukin-7 polypeptides or the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant interleukin-7 polypeptides, immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: April 13, 2021
    Publication date: June 22, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Anne Freimoser-Grundschober, Christian Klein, Laura Lauener, Ekkehard Moessner, Cindy Schulenburg, Pablo Umaña, Eleni Maria Varypataki
  • Antigen binding receptors specific for mutated Fc domains
    Patent number: 11679127
    Abstract: The present invention generally relates to antigen binding receptors capable of specific binding to mutated Fc domains with reduced Fc receptor binding and T cells expressing these antigen binding receptors. More precisely, the present invention relates to T cells, transfected/transduced with an antigen binding receptor which is recruited by specifically binding to/interacting with the mutated Fc domain of therapeutic antibodies. Furthermore, the invention relates to a kit comprising the T cells of the invention and/or nucleic acid molecules, vectors expressing antigen binding receptors of the present invention and (a) tumor targeting antibody/antibodies comprising a mutated Fc domain.
    Type: Grant
    Filed: September 19, 2019
    Date of Patent: June 20, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Kay-Gunnar Stubenrauch, Ekkehard Moessner, Christian Klein, Diana Darowski
  • COMBINATION THERAPY WITH MODIFIED PBMCS AND AN IMMUNOCONJUGATE
    Publication number: 20230181712
    Abstract: The present application provides methods for stimulating an immune response in an individual comprising administering a composition of nucleated cells (e.g., PBMCs) comprising an intracellular exogenous antigen in conjunction with administering an immunoconjugate comprising a variant IL-2 polypeptide and a second polypeptide. The variant IL-2 polypeptide exhibits reduced affinity to the ?-subunit of the IL-2 receptor. The second polypeptide targets a tumor cell or a T cell.
    Type: Application
    Filed: May 10, 2021
    Publication date: June 15, 2023
    Inventors: Pablo UMAÑA, Christian KLEIN, Christine TRUMPFHELLER, Valeria G. NICOLINI, Laura CODARRI DEAK, Scott LOUGHHEAD, Matthew BOOTY
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230183349
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: March 3, 2023
    Publication date: June 15, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Joerg BENZ, Laura CODARRI DEAK, Stefan DENGL, Sebastian FENN, Jens FISCHER, Guy GEORGES, Christian KLEIN, Viktor LEVITSKI, Valeria LIFKE, Oliver PLOETTNER, Stefan SEEBER, Barbara WEISER, Ildiko WUENSCHE, Adrian ZWICK
  • Bispecific antigen binding proteins
    Patent number: 11673945
    Abstract: The present invention relates to bispecific antigen binding proteins, methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: April 8, 2020
    Date of Patent: June 13, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sabine Imhof-Jung, Christian Klein, Joerg Thomas Regula, Wolfgang Schaefer, Juergen Michael Schanzer
  • Augmenting the functionality of user input devices using a digital glove
    Patent number: 11669164
    Abstract: The disclosed technologies address various technical problems, including improving human-computer interaction, by augmenting the functionality provided by user input devices using a digital glove. For example, a digital glove can be utilized to provide pressure sensitivity for non-pressure sensitive touchscreen devices, attribute input made with a digital pen to a user wearing the digital glove, augment the functionality provided by mice and other types of handheld user input devices, augment the functionality provided gaze tracking systems, improve camera-based motion tracking systems, and to augment the functionality provided by speech recognition systems.
    Type: Grant
    Filed: March 16, 2022
    Date of Patent: June 6, 2023
    Assignee: MICROSOFT TECHNOLOGY LICENSING, LLC
    Inventors: Christian Klein, Andrew Stuart Glass, Sang Ho Yoon
  • ANTI-PD1 ANTIBODIES AND METHODS OF USE
    Publication number: 20230143310
    Abstract: The present invention relates to anti-PD1 antibodies and methods of using the same.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 11, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: JOERG BENZ, LAURA CODARRI DEAK, STEFAN DENGL, SEBASTIAN FENN, JENS FISCHER, GUY GEORGES, CHRISTIAN KLEIN, VIKTOR LEVITSKI, VALERIA LIFKE, OLIVER PLOETTNER, STEFAN SEEBER, BARBARA WEISER, ILDIKO WUENSCHE, ADRIAN ZWICK
  • AUGMENTING THE FUNCTIONALITY OF USER INPUT DEVICES USING A DIGITAL GLOVE
    Publication number: 20230134764
    Abstract: The disclosed technologies address various technical problems, including improving human-computer interaction, by augmenting the functionality provided by user input devices using a digital glove. For example, a digital glove can be utilized to provide pressure sensitivity for non-pressure sensitive touchscreen devices, attribute input made with a digital pen to a user wearing the digital glove, augment the functionality provided by mice and other types of handheld user input devices, augment the functionality provided gaze tracking systems, improve camera-based motion tracking systems, and to augment the functionality provided by speech recognition systems.
    Type: Application
    Filed: December 29, 2022
    Publication date: May 4, 2023
    Inventors: Christian KLEIN, Andrew Stuart GLASS, Sang Ho YOON
  • Immunoconjugates
    Publication number: 20230134606
    Abstract: The present invention generally relates to immunoconjugates, particularly immunoconjugates comprising a mutant interleukin-2 polypeptide and an antibody that binds to PD-1. In addition, the invention relates to polynucleotide molecules encoding the immunoconjugates, and vectors and host cells comprising such polynucleotide molecules. The invention further relates to methods for producing the mutant immunoconjugates, pharmaceutical compositions comprising the same, and uses thereof.
    Type: Application
    Filed: June 30, 2022
    Publication date: May 4, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Laura Codarri Deak, Christian Klein, Laura Lauener, Valeria G. Nicolini, Stefan Seeber, Pablo Umana, Inja Waldhauer
  • Bispecific antigen binding molecule for a costimulatory TNF receptor
    Patent number: 11639394
    Abstract: The invention relates to bispecific antigen binding molecules comprising (a) at least one moiety capable of specific binding to OX40, and (b) at least one moiety capable of specific binding to epithelial cell adhesion molecule (EpCAM), and to methods of producing these molecules and to methods of using the same.
    Type: Grant
    Filed: September 25, 2019
    Date of Patent: May 2, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Sandra Grau-Richards, Christian Klein, Pablo Umaña, Maria Amann, Laurene Pousse
  • Bispecific antibodies specific for T-cell activating antigens and a tumor antigen and methods of use
    Patent number: 11639397
    Abstract: The present invention relates to bispecific antibodies that specifically bind a T-cell activating antigen and a Tumor Antigen (TA), comprising a first Fab fragment and a second Fab fragment, wherein either the variable regions or the constant regions of the second Fab heavy and light chain are exchanged; and wherein the bispecific antibody does not comprise a Fc domain; methods for their production, pharmaceutical compositions containing said antibodies, and uses thereof.
    Type: Grant
    Filed: May 5, 2014
    Date of Patent: May 2, 2023
    Assignee: Roche Glycart AG
    Inventors: Peter Bruenker, Tanja Fauti, Christiane Neumann, Christian Klein, Pablo Umana
  • Antigen Binding Molecules comprising a TNF family ligand trimer and PD1 binding moiety
    Publication number: 20230123178
    Abstract: The invention relates to novel TNF family ligand trimer-containing antigen binding molecules having at least one moiety capable of specific binding to PD1 and a first and a second polypeptide that are linked to each other by a disulfide bond, the first polypeptide having two ectodomains of a TNF ligand family member or fragments thereof that are connected to each other by a peptide linker and the second polypeptide having a single ectodomain of the same TNF ligand family member or a fragment thereof.
    Type: Application
    Filed: January 28, 2022
    Publication date: April 20, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Claudia Ferrara Koller, Christina Claus, Christian Klein, Stefan Seeber, Maria Amann, Sandra Grau-Richards, Peter Bruenker, Pablo Umana, Viktor Levitski, Ekkehard Moessner
  • PROTEASE-ACTIVATED T CELL BISPECIFIC MOLECULES
    Publication number: 20230119537
    Abstract: The present invention generally relates to novel protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides. The present invention also relates to polynucleotides encoding such protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides, and vectors and host cells comprising such polynucleotides. The invention further relates to methods for producing the protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides of the invention, and to methods of using these protease-activatable T cell activating bispecific molecules and idiotype-specific polypeptides in the treatment of disease.
    Type: Application
    Filed: June 17, 2022
    Publication date: April 20, 2023
    Inventors: Peter BRUENKER, Rebecca CROASDALE-WOOD, Christian KLEIN, Juergen Michael SCHANZER, Kay-Gunnar STUBENRAUCH, Pablo UMANA, Martina GEIGER, Eric SULLIVAN, Jigar PATEL
  • Combination therapy of T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists
    Patent number: 11613587
    Abstract: The present invention generally relates to T cell activating bispecific antigen binding molecules, PD-1 axis binding antagonists, and in particular to combination therapies employing such T cell activating bispecific antigen binding molecules and PD-1 axis binding antagonists, and their use of these combination therapies for the treatment of cancer.
    Type: Grant
    Filed: August 7, 2020
    Date of Patent: March 28, 2023
    Assignee: Hoffmann-La Roche Inc.
    Inventors: Christian Klein, Vaios Karanikas, Pablo Umana, Alfred Zippelius, Daniela Stefanie Thommen, Jens Schreiner
  • 4-1BBL TRIMER-CONTAINING ANTIGEN BINDING MOLECULES
    Publication number: 20230086210
    Abstract: The invention relates to 4-1BBL trimer-containing antigen binding molecules comprising at least one antigen binding domain capable of specific binding to PD-L1 and their use in the treatment of cancer.
    Type: Application
    Filed: July 8, 2022
    Publication date: March 23, 2023
    Applicant: Hoffmann-La Roche Inc.
    Inventors: Christina CLAUS, Claudia FERRARA KOLLER, Christian Klein, Pablo Umana